Definition for Code SystemSubstanceGlycosylationTypeExample

<?xml version="1.0" encoding="UTF-8"?>

<CodeSystem xmlns="http://hl7.org/fhir">
  <id value="substance-glycosylation-type"/> 
  <meta> 
    <lastUpdated value="2026-07-04T18:53:58.933+00:00"/> 
  </meta> 
  <text> 
    <status value="generated"/> 
    <div xmlns="http://www.w3.org/1999/xhtml">
      <p class="res-header-id">
        <b> Generated Narrative: CodeSystem substance-glycosylation-type</b> 
      </p> 
      <a name="substance-glycosylation-type"> </a> 
      <a name="hcsubstance-glycosylation-type"> </a> 
      <p> This case-sensitive code system 
        <code> http://hl7.org/fhir/substance-glycosylation-type</code>  defines the following codes:
      </p> 
      <table class="codes">
        <tr> 
          <td style="white-space:nowrap">
            <b> Code</b> 
          </td> 
          <td> 
            <b> Display</b> 
          </td> 
          <td> 
            <b> Definition</b> 
          </td> 
        </tr> 
        <tr> 
          <td style="white-space:nowrap">human
            <a name="substance-glycosylation-type-human"> </a> 
          </td> 
          <td> Human</td> 
          <td> Glycosylation pattern from human cell lines (e.g. HEK293, PER.C6). No non-human
             glycan epitopes.</td> 
        </tr> 
        <tr> 
          <td style="white-space:nowrap">mammalian
            <a name="substance-glycosylation-type-mammalian"> </a> 
          </td> 
          <td> Mammalian (non-human)</td> 
          <td> Glycosylation pattern from non-human mammalian cell lines such as CHO, BHK or NS0.
             The most common pattern for therapeutic monoclonal antibodies.</td> 
        </tr> 
        <tr> 
          <td style="white-space:nowrap">old-world-monkey
            <a name="substance-glycosylation-type-old-world-monkey"> </a> 
          </td> 
          <td> Old World Monkey</td> 
          <td> Glycosylation pattern from old world monkey cell lines such as Vero or COS. Often
             used for vaccine production.</td> 
        </tr> 
        <tr> 
          <td style="white-space:nowrap">mouse
            <a name="substance-glycosylation-type-mouse"> </a> 
          </td> 
          <td> Murine</td> 
          <td> Glycosylation pattern from murine cell lines such as NS0 or SP2/0 hybridoma. Carries
             the alpha-1,3-galactose epitope which can be immunogenic in humans.</td> 
        </tr> 
        <tr> 
          <td style="white-space:nowrap">mammalian-afucosylated
            <a name="substance-glycosylation-type-mammalian-afucosylated"> </a> 
          </td> 
          <td> Mammalian, afucosylated</td> 
          <td> Glycosylation pattern from engineered mammalian cell lines lacking fucosyltransferase
             (e.g. Potelligent), producing antibodies with enhanced ADCC activity.</td> 
        </tr> 
        <tr> 
          <td style="white-space:nowrap">avian
            <a name="substance-glycosylation-type-avian"> </a> 
          </td> 
          <td> Avian</td> 
          <td> Glycosylation pattern from egg-derived or avian cell line production. Common for
             influenza vaccines.</td> 
        </tr> 
        <tr> 
          <td style="white-space:nowrap">insect
            <a name="substance-glycosylation-type-insect"> </a> 
          </td> 
          <td> Insect cell</td> 
          <td> Glycosylation pattern from insect cell expression systems such as baculovirus/Sf9.
             Used for some recombinant proteins and vaccines.</td> 
        </tr> 
        <tr> 
          <td style="white-space:nowrap">yeast
            <a name="substance-glycosylation-type-yeast"> </a> 
          </td> 
          <td> Yeast</td> 
          <td> Native yeast glycosylation pattern (e.g. Saccharomyces cerevisiae). Examples include
             insulin and hepatitis B surface antigen.</td> 
        </tr> 
        <tr> 
          <td style="white-space:nowrap">yeast-humanised
            <a name="substance-glycosylation-type-yeast-humanised"> </a> 
          </td> 
          <td> Yeast, humanised</td> 
          <td> Glycosylation pattern from glyco-engineered yeast (e.g. Pichia pastoris GlycoFi
             systems) that produces human-like glycan structures.</td> 
        </tr> 
        <tr> 
          <td style="white-space:nowrap">plant
            <a name="substance-glycosylation-type-plant"> </a> 
          </td> 
          <td> Plant</td> 
          <td> Glycosylation pattern from plant or plant cell culture production (e.g. taliglucerase
             alfa from carrot cells).</td> 
        </tr> 
        <tr> 
          <td style="white-space:nowrap">bacterial
            <a name="substance-glycosylation-type-bacterial"> </a> 
          </td> 
          <td> Bacterial</td> 
          <td> Bacterial expression (typically E. coli). Generally unglycosylated; included for
             completeness when the substance has been characterised as such.</td> 
        </tr> 
      </table> 
    </div> 
  </text> 
  <extension url="http://hl7.org/fhir/StructureDefinition/structuredefinition-wg">
    <valueCode value="brr"/> 
  </extension> 
  <extension url="http://hl7.org/fhir/StructureDefinition/structuredefinition-standards-status">
    <valueCode value="informative"/> 
  </extension> 
  <extension url="http://hl7.org/fhir/StructureDefinition/structuredefinition-fmm">
    <valueInteger value="1"/> 
  </extension> 
  <url value="http://hl7.org/fhir/substance-glycosylation-type"/> 
  <version value="6.0.0-ballot4"/> 
  <name value="SubstanceGlycosylationTypeExample"/> 
  <title value="Substance Glycosylation Type"/> 
  <status value="active"/> 
  <experimental value="true"/> 
  <date value="2026-06-30"/> 
  <publisher value="HL7 (FHIR Project)"/> 
  <contact> 
    <telecom> 
      <system value="url"/> 
      <value value="http://hl7.org/fhir"/> 
    </telecom> 
    <telecom> 
      <system value="email"/> 
      <value value="fhir@lists.hl7.org"/> 
    </telecom> 
  </contact> 
  <description value="A categorical pattern of glycosylation for a substance, typically derived from
   the production cell line or source organism. Applicable to proteins and structurally
   diverse substances (notably vaccines) per ISO 11238."/> 
  <jurisdiction> 
    <coding> 
      <system value="http://unstats.un.org/unsd/methods/m49/m49.htm"/> 
      <code value="001"/> 
      <display value="World"/> 
    </coding> 
  </jurisdiction> 
  <caseSensitive value="true"/> 
  <valueSet value="http://hl7.org/fhir/ValueSet/substance-glycosylation-type"/> 
  <content value="complete"/> 
  <concept> 
    <code value="human"/> 
    <display value="Human"/> 
    <definition value="Glycosylation pattern from human cell lines (e.g. HEK293, PER.C6). No non-human
     glycan epitopes."/> 
  </concept> 
  <concept> 
    <code value="mammalian"/> 
    <display value="Mammalian (non-human)"/> 
    <definition value="Glycosylation pattern from non-human mammalian cell lines such as CHO, BHK or NS0.
     The most common pattern for therapeutic monoclonal antibodies."/> 
  </concept> 
  <concept> 
    <code value="old-world-monkey"/> 
    <display value="Old World Monkey"/> 
    <definition value="Glycosylation pattern from old world monkey cell lines such as Vero or COS. Often
     used for vaccine production."/> 
  </concept> 
  <concept> 
    <code value="mouse"/> 
    <display value="Murine"/> 
    <definition value="Glycosylation pattern from murine cell lines such as NS0 or SP2/0 hybridoma. Carries
     the alpha-1,3-galactose epitope which can be immunogenic in humans."/> 
  </concept> 
  <concept> 
    <code value="mammalian-afucosylated"/> 
    <display value="Mammalian, afucosylated"/> 
    <definition value="Glycosylation pattern from engineered mammalian cell lines lacking fucosyltransferase
     (e.g. Potelligent), producing antibodies with enhanced ADCC activity."/> 
  </concept> 
  <concept> 
    <code value="avian"/> 
    <display value="Avian"/> 
    <definition value="Glycosylation pattern from egg-derived or avian cell line production. Common for
     influenza vaccines."/> 
  </concept> 
  <concept> 
    <code value="insect"/> 
    <display value="Insect cell"/> 
    <definition value="Glycosylation pattern from insect cell expression systems such as baculovirus/Sf9.
     Used for some recombinant proteins and vaccines."/> 
  </concept> 
  <concept> 
    <code value="yeast"/> 
    <display value="Yeast"/> 
    <definition value="Native yeast glycosylation pattern (e.g. Saccharomyces cerevisiae). Examples include
     insulin and hepatitis B surface antigen."/> 
  </concept> 
  <concept> 
    <code value="yeast-humanised"/> 
    <display value="Yeast, humanised"/> 
    <definition value="Glycosylation pattern from glyco-engineered yeast (e.g. Pichia pastoris GlycoFi
     systems) that produces human-like glycan structures."/> 
  </concept> 
  <concept> 
    <code value="plant"/> 
    <display value="Plant"/> 
    <definition value="Glycosylation pattern from plant or plant cell culture production (e.g. taliglucerase
     alfa from carrot cells)."/> 
  </concept> 
  <concept> 
    <code value="bacterial"/> 
    <display value="Bacterial"/> 
    <definition value="Bacterial expression (typically E. coli). Generally unglycosylated; included for
     completeness when the substance has been characterised as such."/> 
  </concept> 
</CodeSystem>